Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Multitarget cannabinoids as novel strategy for Alzheimer disease.

González-Naranjo P, Campillo NE, Pérez C, Páez JA.

Curr Alzheimer Res. 2013 Mar;10(3):229-39.

PMID:
23369066
2.

Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.

González-Naranjo P, Pérez-Macias N, Campillo NE, Pérez C, Arán VJ, Girón R, Sánchez-Robles E, Martín MI, Gómez-Cañas M, García-Arencibia M, Fernández-Ruiz J, Páez JA.

Eur J Med Chem. 2014 Feb 12;73:56-72. doi: 10.1016/j.ejmech.2013.11.026.

PMID:
24378710
3.

Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.

Campiani G, Fattorusso C, Butini S, Gaeta A, Agnusdei M, Gemma S, Persico M, Catalanotti B, Savini L, Nacci V, Novellino E, Holloway HW, Greig NH, Belinskaya T, Fedorko JM, Saxena A.

J Med Chem. 2005 Mar 24;48(6):1919-29.

PMID:
15771436
4.

Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.

Bolea I, Juárez-Jiménez J, de Los Ríos C, Chioua M, Pouplana R, Luque FJ, Unzeta M, Marco-Contelles J, Samadi A.

J Med Chem. 2011 Dec 22;54(24):8251-70. doi: 10.1021/jm200853t.

PMID:
22023459
5.

Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease.

Makhaeva GF, Lushchekina SV, Boltneva NP, Sokolov VB, Grigoriev VV, Serebryakova OG, Vikhareva EA, Aksinenko AY, Barreto GE, Aliev G, Bachurin SO.

Sci Rep. 2015 Aug 18;5:13164. doi: 10.1038/srep13164.

6.

Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11H-indeno-[1,2-b]-quinolin-10-ylamine derivatives.

Rampa A, Bisi A, Belluti F, Gobbi S, Valenti P, Andrisano V, Cavrini V, Cavalli A, Recanatini M.

Bioorg Med Chem. 2000 Mar;8(3):497-506.

PMID:
10732965
7.

[Design of acetylcholinesterase inhibitor for Alzheimer's disease therapy: from multi-binding site inhibitors to multi-target directed ligands].

Yang WC, Sun Q, Yu NX, Zhu XL, Yang GF.

Yao Xue Xue Bao. 2012 Mar;47(3):313-21. Review. Chinese.

PMID:
22645754
8.

Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents.

Galdeano C, Viayna E, Arroyo P, Bidon-Chanal A, Blas JR, Muñoz-Torrero D, Luque FJ.

Curr Pharm Des. 2010;16(25):2818-36. Review.

PMID:
20698824
9.

A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.

Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, Lee B, Ingram DK, Lahiri DK.

Curr Med Res Opin. 2001;17(3):159-65. Review.

PMID:
11900310
10.

Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase.

Huang L, Luo Z, He F, Lu J, Li X.

Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. doi: 10.1016/j.bmc.2010.04.063.

PMID:
20471843
11.

Synthesis and biological evaluation of 1,3,4-thiadiazole analogues as novel AChE and BuChE inhibitors.

Skrzypek A, Matysiak J, Niewiadomy A, Bajda M, Szymański P.

Eur J Med Chem. 2013 Apr;62:311-9. doi: 10.1016/j.ejmech.2012.12.060.

PMID:
23376249
12.

Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.

Samadi A, de los Ríos C, Bolea I, Chioua M, Iriepa I, Moraleda I, Bartolini M, Andrisano V, Gálvez E, Valderas C, Unzeta M, Marco-Contelles J.

Eur J Med Chem. 2012 Jun;52:251-62. doi: 10.1016/j.ejmech.2012.03.022.

PMID:
22503231
13.

2-(2-indolyl-)-4(3H)-quinazolines derivates as new inhibitors of AChE: design, synthesis, biological evaluation and molecular modelling.

Li Z, Wang B, Hou JQ, Huang SL, Ou TM, Tan JH, An LK, Li D, Gu LQ, Huang ZS.

J Enzyme Inhib Med Chem. 2013 Jun;28(3):583-92. doi: 10.3109/14756366.2012.663363.

PMID:
22380775
14.

Inhibition of human cholinesterases by drugs used to treat Alzheimer disease.

Darvesh S, Walsh R, Kumar R, Caines A, Roberts S, Magee D, Rockwood K, Martin E.

Alzheimer Dis Assoc Disord. 2003 Apr-Jun;17(2):117-26.

PMID:
12794390
15.

Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications.

Musilek K, Komloova M, Zavadova V, Holas O, Hrabinova M, Pohanka M, Dohnal V, Nachon F, Dolezal M, Kuca K, Jung YS.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6. doi: 10.1016/j.bmcl.2010.01.034.

PMID:
20138518
16.

Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.

Brunhofer G, Fallarero A, Karlsson D, Batista-Gonzalez A, Shinde P, Gopi Mohan C, Vuorela P.

Bioorg Med Chem. 2012 Nov 15;20(22):6669-79. doi: 10.1016/j.bmc.2012.09.040.

PMID:
23062825
17.

Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors.

Savini L, Gaeta A, Fattorusso C, Catalanotti B, Campiani G, Chiasserini L, Pellerano C, Novellino E, McKissic D, Saxena A.

J Med Chem. 2003 Jan 2;46(1):1-4.

PMID:
12502352
18.

Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.

Kwon YE, Park JY, No KT, Shin JH, Lee SK, Eun JS, Yang JH, Shin TY, Kim DK, Chae BS, Leem JY, Kim KH.

Bioorg Med Chem. 2007 Oct 15;15(20):6596-607.

PMID:
17681794
19.

Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.

Sterling J, Herzig Y, Goren T, Finkelstein N, Lerner D, Goldenberg W, Miskolczi I, Molnar S, Rantal F, Tamas T, Toth G, Zagyva A, Zekany A, Finberg J, Lavian G, Gross A, Friedman R, Razin M, Huang W, Krais B, Chorev M, Youdim MB, Weinstock M.

J Med Chem. 2002 Nov 21;45(24):5260-79.

PMID:
12431053
20.

Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase.

Catto M, Pisani L, Leonetti F, Nicolotti O, Pesce P, Stefanachi A, Cellamare S, Carotti A.

Bioorg Med Chem. 2013 Jan 1;21(1):146-52. doi: 10.1016/j.bmc.2012.10.045.

PMID:
23199476
Items per page

Supplemental Content

Support Center